Head-To-Head Contrast: Onconetix (NASDAQ:ONCO) and Incyte (NASDAQ:INCY)

Onconetix (NASDAQ:ONCO) and Incyte (NASDAQ:INCY) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability and analyst recommendations.

Profitability

This table compares Onconetix and Incyte’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Onconetix	-1,717.50%	8.24%	2.90%
Incyte	25.03%	26.34%	18.71%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Onconetix and Incyte, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Onconetix	1	0	0	0	1.00
Incyte	1	11	9	0	2.38

Incyte has a consensus price target of $103.44, indicating a potential upside of 13.95%. Given Incyte’s stronger consensus rating and higher probable upside, analysts plainly believe Incyte is more favorable than Onconetix.

Risk & Volatility

Onconetix has a beta of 3.51, suggesting that its stock price is 251% more volatile than the S&P 500. Comparatively, Incyte has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500.

Insider & Institutional Ownership

23.9% of Onconetix shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 1.0% of Onconetix shares are owned by company insiders. Comparatively, 17.8% of Incyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Onconetix and Incyte”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Onconetix	$810,000.00	1.19	-$14.03 million	($43.35)	-0.01
Incyte	$5.14 billion	3.51	$1.29 billion	$6.41	14.16

Incyte has higher revenue and earnings than Onconetix. Onconetix is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Summary

Incyte beats Onconetix on 13 of the 14 factors compared between the two stocks.

About Onconetix

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.